Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)
46.54
-0.04 (-0.09%)
Oct 31, 2025, 4:08 PM HKT
HKG:3347 Revenue
Hangzhou Tigermed Consulting had revenue of 1.78B CNY in the quarter ending September 30, 2025, with 3.86% growth. This brings the company's revenue in the last twelve months to 6.56B, down -3.53% year-over-year. In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B, down -10.58%.
Revenue (ttm)
6.56B CNY
Revenue Growth
-3.53%
P/S Ratio
7.48
Revenue / Employee
644.22K CNY
Employees
10,185
Market Cap
53.60B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
| Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
| Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
| Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
| Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |